Clinical trial
Zanubrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma With p53 Protein Expression
NCT06005870 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Zanubrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma With p53 Protein Expression
- Lead sponsor
- Huazhong University of Science and Technology
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 26, 2022
- Completion date
- December 31, 2026
- Enrollment
- 41 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b cell lymphoma